Tecentriq Hybreza
NDC 50242-933 · Genentech, Inc.
Packages
50242-933-01 — 1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-01) / 15 mL in 1 VIAL, SINGLE-DOSE
50242-933-86 — 1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-86) / 15 mL in 1 VIAL, SINGLE-DOSE
Billed under HCPCS
J9024 — Injection, atezolizumab, 5 mg and hyaluronidase-tqjs Medicare Part B payment limit (ASP + 6%): $32.55
Related Codes
Same active ingredient
FDA lists these products with the same active ingredient.
0003-3120 — nivolumab and hyaluronidase-nvhy, 0003-6120 — nivolumab and hyaluronidase-nvhy, 18657-117 — Hyaluronidase, 50242-077 — Trastuzumab and hyaluronidase-oysk, 50242-108 — rituximab and hyaluronidase, 50242-109 — rituximab and hyaluronidase, 50242-245 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-260 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-554 — ocrelizumab and hyaluronidase, 50242-917 — atezolizumab, 50242-918 — atezolizumab, 51662-1555 — HYALURONIDASE, 57894-503 — daratumumab and hyaluronidase-fihj (human recombinant), 57894-510 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-514 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-515 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-522 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 73475-1221 — efgartigimod alfa and hyaluronidase (human recombinant), 73475-3102 — efgartigimod alfa and hyaluronidase (human recombinant)